{'en': 'Novo Nordisk will be late with his insulin Xultophy', 'es': 'Novo Nordisk llegará tarde con su insulina Xultophy'} Image

Novo Nordisk will be late with his insulin Xultophy

fer's profile photo   01/11/2017 10:57 a.m.

In diabetes, being the first implies great advantages.Being a chronic disease of great prevalence, there is great competition among pharmacists for launching new advances.And the Danish Novo Nordisk seems to have stumbled in this race.

Despite having received the approval of its new product-a combination of insulin Tresiba and the Analogue of LPG-1 Victoza called Xultophy-in the United States the same day as its Sanofi rival, on November 21, the French laboratory has reachedFirst the North American market.

Soliqua, also a combination of insulin and analogue of LPG-1, can already be acquired in the US, while Xultophy will have to wait until May to make their appearance due, as they have commented on Novo Nordisk to the specialized environment Fierce Pharma, training needs forPart of the Sales Force of the Danish laboratory.

Thus, the French manufacturer of pharmaceutical products will enjoy four months to get a good market share, launching its product at $ 127 for each 300 dose injector.Novo Nordisk's medicine will have to battle through the price if you want to get a part of the extensive diabetes and US market.

The Danish laboratory does not seem to correct the direction that has led him to announce, at the end of last year, a worldwide cut in his workforce, with up to a thousand affected workers, with the aim of reducing the costs in 2017 up to 150 millioneuros.

fer's profile photo
fer
01/11/2017 10:57 a.m.

@fer - Diabetes Tipo 1 desde 1.998 | FreeStyle Libre 3 | Ypsomed mylife YpsoPump + CamAPS FX | Sin complicaciones. Miembro del equipo de moderación del foro.
Co-Autor de Vivir con Diabetes: El poder de la comunidad online, parte de los ingresos se destinan a financiar el foro de diabetes y mantener la comunidad online activa.

  

And what is the advantage of the new insulin?A prick less?I am not sure the advantage.

Papajesus1's profile photo
Papajesus1
01/14/2017 3:17 p.m.

Padre de Jesús. Bomba insulina y dexcom g4 share. Debut con 18 meses....ya con 7 añitos...Hemo entorno a 7....y mucha lucha diaria.....ya sabéis..poco dormir y bastantes miedos....pero mi niño es feliz luego yo también.

  

It is very good that they manufacture new insulins, but they would have to ensure the effect, duration .. to be able to choose more security.When Lantus came out, they promised a duration of 24 hours with flat action, and it was not so ...

Regina's profile photo
Regina
01/14/2017 7:28 p.m.

Hija de 35 años , diabética desde los 5. Glico: normalmente de 6 , pero 6,7 la última ( 6,2 marcaba el Free)
Fiasp: 4- 4- 3 Toujeo: 20

  

Join the Discussion!

To participate in this thread, please register or log in.